Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS) Assessment in Adults with Motor, Sensory, and Language Barriers, Following Chimeric Antigen Receptor (CAR) T cell Therapy in the Outpatient Setting

Key Points

• ICANS assessment shows varied symptoms in adults with communication barriers, affecting timely intervention.
• Among 30 participants, 67% experienced neurotoxicity symptoms within two months post-CAR T cell therapy.
• Observational analysis in outpatient settings explored the impact of barriers on ICANS assessment.
• Findings suggest the need for tailored approaches to improve ICANS evaluation in neurodiverse adults.